Common use of Interpretation of Patent Judgments Clause in Contracts

Interpretation of Patent Judgments. If any claim in a patent under the Adamas Patent Rights, including any Adamas Memantine Patent Right, or Forest Patent Rights becomes the subject of a judgment, decree or decision of a court, tribunal, or other authority of competent jurisdiction in the Territory, which judgment, decree, or decision is or becomes final (there being no further right of review) and adjudicates the validity, enforceability, scope or infringement of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in the Territory in determining whether a Product is subject to a royalty hereunder, not only as to such claim but also as to all other claims in the Territory to which such construction reasonably applies. If at any time there are two or more conflicting final judgments, decrees, or decisions with respect to the same claim, the decision of the higher tribunal shall thereafter [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. control, but if the tribunals be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control unless and until the majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the latter shall control.

Appears in 3 contracts

Samples: License Agreement, License Agreement (Adamas Pharmaceuticals Inc), License Agreement (Adamas Pharmaceuticals Inc)

AutoNDA by SimpleDocs

Interpretation of Patent Judgments. If any claim in relating to a patent under the Adamas Patent Rights, including any Adamas Memantine Patent Right, or Forest ALNYLAM Patent Rights becomes the subject of a judgment, decree or decision of a [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. court, tribunal, or other authority of competent jurisdiction in the Territoryany country, which judgment, decree, or decision is or becomes final (there being no further right of review) and adjudicates the validity, enforceability, scope scope, or infringement of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in the Territory such country in determining whether a product is a Licensed RNAi Product is subject to a royalty hereunder, not only as to such claim but also as to all other claims in the Territory such country to which such construction reasonably applies. If at any time there are two or more conflicting final judgments, decrees, or decisions with respect to the same claim, the decision of the higher tribunal shall thereafter [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. control, but if the tribunals tribunal be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control unless and until the majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the latter shall control.

Appears in 2 contracts

Samples: License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Biotech Inc)

AutoNDA by SimpleDocs

Interpretation of Patent Judgments. If any claim in relating to a patent under the Adamas Patent Rights[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, including any Adamas Memantine Patent RightMARKED BY BRACKETS, or Forest HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. ALNYLAM Patent Rights becomes the subject of a judgment, decree or decision of a court, tribunal, or other authority of competent jurisdiction in the Territoryany country, which judgment, decree, or decision is or becomes final (there being no further right of review) and adjudicates the validity, enforceability, scope scope, or infringement of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in the Territory such country in determining whether a product is a Licensed RNAi Product is subject to a royalty hereunder, not only as to such claim but also as to all other claims in the Territory such country to which such construction reasonably applies. If at any time there are two or more conflicting final judgments, decrees, or decisions with respect to the same claim, the decision of the higher tribunal shall thereafter [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. control, but if the tribunals tribunal be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control unless and until the majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the latter shall control.

Appears in 2 contracts

Samples: License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Biotech Inc)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!